These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 27230636)

  • 21. Use of HbA1c in clinical practice: New insights.
    Bloomgarden Z
    J Diabetes; 2021 Apr; 13(4):280-281. PubMed ID: 33427383
    [No Abstract]   [Full Text] [Related]  

  • 22. National survey: Evaluation of cardiovascular risk factors in Thai patients with type 2 diabetes and chronic kidney disease after the development of cardiovascular disease.
    Changsirikulchai S; Sangthawan P; Janma J; Sripaiboonkij N; Rattanamongkolgul S; Thinkhamrop B
    Nephrology (Carlton); 2018 Jan; 23(1):53-59. PubMed ID: 27608176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Should early surgical intervention be recommended for obese patients with type two diabetes mellitus?
    Ahmad Z; Ahmad A
    Prim Care Diabetes; 2019 Apr; 13(2):187. PubMed ID: 29724666
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study.
    Pintaudi B; Scatena A; Piscitelli G; Frison V; Corrao S; Manicardi V; Graziano G; Rossi MC; Gallo M; Mannino D; Di Bartolo P; Nicolucci A
    Cardiovasc Diabetol; 2021 Mar; 20(1):59. PubMed ID: 33676499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association.
    Poirier P; Cornier MA; Mazzone T; Stiles S; Cummings S; Klein S; McCullough PA; Ren Fielding C; Franklin BA;
    Circulation; 2011 Apr; 123(15):1683-701. PubMed ID: 21403092
    [No Abstract]   [Full Text] [Related]  

  • 26. Cardiovascular Risk and Safety Evaluation of a Dual Peroxisome Proliferator-Activated Receptor-Alpha/Gamma Agonist, Aleglitazar, in Patients With Type 2 Diabetes: A Meta-analysis.
    Han CL; Qu CZ
    J Cardiovasc Pharmacol; 2020 Apr; 75(4):351-357. PubMed ID: 31929323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High baseline C-reactive protein levels predict partial type 2 diabetes mellitus remission after biliopancreatic diversion.
    Bonaventura A; Liberale L; Carbone F; Scopinaro N; Camerini G; Papadia FS; Cordera R; Dallegri F; Adami GF; Montecucco F
    Nutr Metab Cardiovasc Dis; 2017 May; 27(5):423-429. PubMed ID: 28284664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial.
    Masmiquel L; Leiter LA; Vidal J; Bain S; Petrie J; Franek E; Raz I; Comlekci A; Jacob S; van Gaal L; Baeres FM; Marso SP; Eriksson M;
    Cardiovasc Diabetol; 2016 Feb; 15():29. PubMed ID: 26864124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters.
    Lamos EM; Levitt DL; Munir KM
    Prim Care Diabetes; 2016 Feb; 10(1):60-5. PubMed ID: 26670921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How to prevent diabetes-triggered heart disease.
    An S; Zhao B; Zhang X; Liu Q
    Eur J Prev Cardiol; 2018 Nov; 25(16):1789. PubMed ID: 29771157
    [No Abstract]   [Full Text] [Related]  

  • 31. Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project.
    Arnold SV; Inzucchi SE; Tang F; McGuire DK; Mehta SN; Maddox TM; Goyal A; Sperling LS; Einhorn D; Wong ND; Khunti K; Lam CS; Kosiborod M
    Eur J Prev Cardiol; 2017 Oct; 24(15):1637-1645. PubMed ID: 28870145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Divergent effects of various diabetes drugs on cardiovascular prognosis.
    Bell DS; Patil HR; O'Keefe JH
    Rev Cardiovasc Med; 2013; 14(2-4):e107-22. PubMed ID: 24448252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Postprandial glucose monitoring further improved glycemia, lipids, and weight in persons with type 2 diabetes mellitus who had already reached hemoglobin A1c goal.
    Zhang DA; Katznelson L; Li M
    J Diabetes Sci Technol; 2012 Mar; 6(2):289-93. PubMed ID: 22538137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of low fasting C-peptide levels with cardiovascular risk, visit-to-visit glucose variation and severe hypoglycemia in the Veterans Affairs Diabetes Trial (VADT).
    Koska J; Nuyujukian DS; Bahn GD; Zhou JJ; Reaven PD
    Cardiovasc Diabetol; 2021 Dec; 20(1):232. PubMed ID: 34879878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Zhao D; Liu H; Dong P
    J Hum Hypertens; 2019 Apr; 33(4):327-339. PubMed ID: 30443007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The obesity paradox: an endocrine perspective.
    Cheung YM; Joham A; Marks S; Teede H
    Intern Med J; 2017 Jul; 47(7):727-733. PubMed ID: 27643504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use.
    Verma S; Leiter LA; Mazer CD; Bain SC; Buse J; Marso S; Nauck M; Zinman B; Bosch-Traberg H; Rasmussen S; Michelsen MM; Bhatt DL
    Circulation; 2018 Oct; 138(15):1605-1607. PubMed ID: 30354517
    [No Abstract]   [Full Text] [Related]  

  • 38. Impact of a Mediterranean Dietary Pattern and Its Components on Cardiovascular Risk Factors, Glucose Control, and Body Weight in People with Type 2 Diabetes: A Real-Life Study.
    Vitale M; Masulli M; Calabrese I; Rivellese AA; Bonora E; Signorini S; Perriello G; Squatrito S; Buzzetti R; Sartore G; Babini AC; Gregori G; Giordano C; Clemente G; Grioni S; Dolce P; Riccardi G; Vaccaro O;
    Nutrients; 2018 Aug; 10(8):. PubMed ID: 30103444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of pre-diabetes and diabetes on cardiovascular outcomes.
    Anselmino M; Sillano D
    Curr Vasc Pharmacol; 2012 Nov; 10(6):680-3. PubMed ID: 23259552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Socioeconomic position and cardiovascular risk factors among people with screen-detected Type 2 DM: six-year follow-up of the ADDITION-Denmark trial.
    Dalsgaard EM; Vestergaard M; Skriver MV; Borch-Johnsen K; Lauritzen T; Sandbaek A
    Prim Care Diabetes; 2014 Dec; 8(4):322-9. PubMed ID: 24613817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.